Nifty
Sensex
:
:
23465.60
76992.77
66.70 (0.29%)
181.87 (0.24%)

Pharmaceuticals & Drugs

Rating :
51/99

BSE: 526953 | NSE: VENUSREM

378.00
14-Jun-2024
  • Open
  • High
  • Low
  • Previous Close
  •  379.35
  •  385.85
  •  373.30
  •  375.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  106958
  •  405.84
  •  430.00
  •  222.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 504.87
  • 17.72
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 478.10
  • N/A
  • 1.04

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 41.76%
  • 3.01%
  • 46.89%
  • FII
  • DII
  • Others
  • 1.48%
  • 0.00%
  • 6.86%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.25
  • 11.53
  • 0.45

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -7.98
  • 13.11
  • 2.28

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -8.46
  • -
  • -24.51

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.24
  • 8.26
  • 12.33

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.51
  • 0.68
  • 0.89

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.73
  • 6.89
  • 6.02

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
195.16
155.64
25.39%
143.42
116.90
22.69%
167.72
139.89
19.89%
95.15
143.08
-33.50%
Expenses
175.68
131.03
34.08%
131.38
108.80
20.75%
149.93
126.92
18.13%
84.75
128.57
-34.08%
EBITDA
19.48
24.61
-20.85%
12.04
8.10
48.64%
17.79
12.97
37.16%
10.40
14.51
-28.33%
EBIDTM
9.98%
15.81%
8.39%
6.93%
10.61%
9.27%
10.93%
10.14%
Other Income
3.92
3.41
14.96%
2.35
3.81
-38.32%
3.05
1.79
70.39%
2.26
1.44
56.94%
Interest
0.02
0.00
0
0.07
0.15
-53.33%
0.06
0.00
0
0.06
0.26
-76.92%
Depreciation
5.91
8.29
-28.71%
6.54
7.22
-9.42%
6.44
8.99
-28.36%
7.55
7.80
-3.21%
PBT
17.47
19.73
-11.45%
7.78
4.54
71.37%
14.34
5.77
148.53%
5.05
7.89
-35.99%
Tax
6.96
8.67
-19.72%
0.93
1.25
-25.60%
4.40
0.44
900.00%
3.87
1.00
287.00%
PAT
10.51
11.06
-4.97%
6.85
3.29
108.21%
9.94
5.33
86.49%
1.18
6.89
-82.87%
PATM
5.39%
7.11%
4.78%
2.81%
5.93%
3.81%
1.24%
4.82%
EPS
7.86
8.27
-4.96%
5.12
2.46
108.13%
7.43
3.99
86.22%
0.88
5.15
-82.91%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
601.45
555.51
600.18
548.12
339.33
321.89
372.41
400.04
418.27
463.99
541.56
Net Sales Growth
8.27%
-7.44%
9.50%
61.53%
5.42%
-13.57%
-6.91%
-4.36%
-9.85%
-14.32%
 
Cost Of Goods Sold
354.69
330.99
386.98
340.79
174.31
181.95
205.08
227.07
238.51
268.94
300.00
Gross Profit
246.76
224.51
213.20
207.33
165.02
139.94
167.33
172.97
179.77
195.05
241.55
GP Margin
41.03%
40.42%
35.52%
37.83%
48.63%
43.47%
44.93%
43.24%
42.98%
42.04%
44.60%
Total Expenditure
541.74
495.31
538.07
494.35
298.52
289.37
332.94
349.32
337.11
374.81
403.33
Power & Fuel Cost
-
5.52
4.71
4.58
4.73
4.86
4.29
4.14
4.01
3.80
3.38
% Of Sales
-
0.99%
0.78%
0.84%
1.39%
1.51%
1.15%
1.03%
0.96%
0.82%
0.62%
Employee Cost
-
57.05
52.33
46.02
46.02
42.10
39.31
34.27
32.44
32.36
30.45
% Of Sales
-
10.27%
8.72%
8.40%
13.56%
13.08%
10.56%
8.57%
7.76%
6.97%
5.62%
Manufacturing Exp.
-
32.40
31.57
22.86
20.84
21.01
36.10
42.48
15.70
17.29
22.10
% Of Sales
-
5.83%
5.26%
4.17%
6.14%
6.53%
9.69%
10.62%
3.75%
3.73%
4.08%
General & Admin Exp.
-
20.70
16.67
16.45
17.57
11.85
13.52
13.26
11.97
15.67
14.74
% Of Sales
-
3.73%
2.78%
3.00%
5.18%
3.68%
3.63%
3.31%
2.86%
3.38%
2.72%
Selling & Distn. Exp.
-
48.40
45.80
63.64
35.05
27.60
34.65
28.10
34.48
36.75
32.65
% Of Sales
-
8.71%
7.63%
11.61%
10.33%
8.57%
9.30%
7.02%
8.24%
7.92%
6.03%
Miscellaneous Exp.
-
0.26
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
32.65
% Of Sales
-
0.05%
0%
0%
0%
0%
0%
0%
0%
0%
0%
EBITDA
59.71
60.20
62.11
53.77
40.81
32.52
39.47
50.72
81.16
89.18
138.23
EBITDA Margin
9.93%
10.84%
10.35%
9.81%
12.03%
10.10%
10.60%
12.68%
19.40%
19.22%
25.52%
Other Income
11.58
10.32
8.31
19.63
5.31
6.09
2.39
4.28
2.01
0.68
0.47
Interest
0.21
0.29
0.48
13.02
13.34
25.41
35.56
36.38
37.98
41.21
29.40
Depreciation
26.44
32.30
33.53
35.28
32.01
33.98
33.83
40.26
41.68
46.00
40.22
PBT
44.64
37.93
36.41
25.11
0.78
-20.77
-27.53
-21.64
3.51
2.65
69.08
Tax
16.16
11.36
-4.32
-13.21
1.96
-1.15
3.16
-4.56
1.81
-2.51
4.78
Tax Rate
36.20%
29.95%
-11.86%
-27.21%
-24.41%
3.87%
-11.48%
21.07%
51.57%
-94.72%
6.92%
PAT
28.48
26.57
40.72
61.77
-10.00
-28.57
-30.69
-17.08
1.70
5.16
64.30
PAT before Minority Interest
28.48
26.57
40.72
61.77
-10.00
-28.57
-30.69
-17.08
1.70
5.16
64.30
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
4.74%
4.78%
6.78%
11.27%
-2.95%
-8.88%
-8.24%
-4.27%
0.41%
1.11%
11.87%
PAT Growth
7.19%
-34.75%
-34.08%
-
-
-
-
-
-67.05%
-91.98%
 
EPS
21.25
19.83
30.39
46.10
-7.46
-21.32
-22.90
-12.75
1.27
3.85
47.99

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
460.34
440.45
400.28
323.37
332.52
361.91
388.67
437.62
456.68
461.61
Share Capital
13.37
13.37
12.34
12.34
12.34
12.34
12.34
11.44
11.44
11.44
Total Reserves
446.97
427.08
374.19
311.03
320.18
349.57
376.33
426.18
445.24
450.17
Non-Current Liabilities
58.17
45.95
58.12
95.82
136.68
158.47
179.52
212.05
221.55
161.75
Secured Loans
0.00
0.00
0.09
24.19
61.29
86.60
112.69
134.57
150.95
114.76
Unsecured Loans
38.68
38.68
46.74
47.87
54.73
50.84
49.13
56.47
51.34
25.22
Long Term Provisions
8.85
7.95
7.38
6.63
5.32
4.50
4.29
3.79
3.78
3.31
Current Liabilities
82.57
92.74
97.45
224.58
263.62
230.38
196.81
193.14
162.83
210.99
Trade Payables
50.84
50.17
71.36
36.70
36.00
29.33
29.73
25.14
29.56
31.22
Other Current Liabilities
27.23
37.76
21.10
101.70
110.30
78.47
46.16
42.71
15.96
54.70
Short Term Borrowings
3.61
4.06
4.30
85.58
112.80
121.26
119.16
123.32
115.40
110.08
Short Term Provisions
0.89
0.75
0.68
0.61
4.52
1.32
1.76
1.97
1.91
14.99
Total Liabilities
601.08
579.14
555.85
643.77
732.82
750.76
765.00
842.81
841.06
834.35
Net Block
215.96
240.94
261.68
289.37
364.45
389.20
406.18
452.48
443.65
439.46
Gross Block
603.75
612.50
616.32
623.96
707.02
702.77
686.50
679.57
641.12
587.38
Accumulated Depreciation
387.78
371.57
354.63
334.59
342.57
313.57
280.32
227.09
197.47
147.93
Non Current Assets
278.12
301.10
321.82
349.77
467.39
490.50
505.60
565.75
607.85
562.24
Capital Work in Progress
26.10
25.23
25.11
24.63
64.76
64.76
66.25
80.37
78.30
67.80
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
33.95
33.36
35.03
35.77
38.18
36.53
33.17
32.90
85.91
54.98
Other Non Current Assets
2.11
1.57
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
322.96
278.04
234.03
294.00
265.43
260.27
259.41
277.07
233.21
272.11
Current Investments
20.13
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
119.94
125.64
119.99
141.12
142.73
138.17
140.60
143.29
142.87
142.26
Sundry Debtors
76.66
38.60
32.04
30.69
38.04
47.27
47.29
61.59
63.22
64.99
Cash & Bank
53.72
50.40
31.42
2.13
2.81
3.98
3.56
7.07
3.62
4.41
Other Current Assets
52.51
5.01
5.70
55.72
81.85
70.84
67.96
65.12
23.51
60.47
Short Term Loans & Adv.
50.73
58.39
44.88
64.34
76.70
66.00
67.96
65.12
23.51
60.47
Net Current Assets
240.39
185.30
136.59
69.43
1.81
29.88
62.59
83.93
70.38
61.12
Total Assets
601.08
579.14
555.85
643.77
732.82
750.77
765.01
842.82
841.06
834.35

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
36.63
41.10
131.84
77.60
45.33
31.19
58.93
46.88
67.80
52.65
PBT
37.93
36.41
25.11
0.78
-20.77
-27.53
-21.64
3.51
2.65
69.08
Adjustment
23.33
26.33
21.89
41.56
60.72
66.24
70.61
56.41
83.56
37.21
Changes in Working Capital
-24.63
-21.64
61.39
20.82
5.37
-7.52
9.96
-13.04
-18.40
-53.65
Cash after chg. in Working capital
36.63
41.10
108.39
63.16
45.33
31.19
58.93
46.88
67.80
52.65
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
23.44
14.44
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-50.83
-16.73
56.49
-4.75
-11.33
-11.48
-18.32
2.92
-67.18
-94.66
Net Fixed Assets
8.82
3.42
7.56
124.42
-5.05
-11.74
18.95
-50.18
-67.39
-93.77
Net Investments
-20.13
0.00
0.00
0.00
0.00
28.60
0.00
0.00
0.00
0.00
Others
-39.52
-20.15
48.93
-129.17
-6.28
-28.34
-37.27
53.10
0.21
-0.89
Cash from Financing Activity
-0.57
-9.48
-162.24
-73.00
-35.17
-39.23
-44.13
-46.35
-1.42
40.06
Net Cash Inflow / Outflow
-14.77
14.90
26.09
-0.15
-1.17
-19.52
-3.51
3.46
-0.79
-1.95
Opening Cash & Equivalents
43.26
28.88
1.94
2.03
3.98
0.00
7.07
3.62
4.41
6.36
Closing Cash & Equivalent
21.21
43.26
28.88
1.94
2.81
-19.52
3.56
7.07
3.62
4.41

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
344.38
329.50
313.18
262.01
269.42
293.23
314.92
382.47
399.13
403.43
ROA
4.50%
7.18%
10.30%
-1.45%
-3.85%
-4.05%
-2.12%
0.20%
0.62%
8.29%
ROE
5.90%
9.85%
17.40%
-3.05%
-8.23%
-8.18%
-4.13%
0.38%
1.12%
15.38%
ROCE
7.75%
7.89%
12.37%
0.90%
-0.67%
1.17%
2.00%
5.35%
5.74%
14.06%
Fixed Asset Turnover
0.91
0.98
0.88
0.51
0.46
0.54
0.59
0.63
0.76
0.99
Receivable days
37.87
21.48
20.89
36.97
48.37
46.34
49.67
54.45
50.42
37.72
Inventory Days
80.68
74.69
86.94
152.66
159.26
136.61
129.51
124.86
112.15
90.94
Payable days
55.69
57.31
57.86
42.82
37.91
30.30
26.74
26.74
27.25
21.28
Cash Conversion Cycle
62.86
38.86
49.96
146.80
169.72
152.65
152.44
152.57
135.32
107.37
Total Debt/Equity
0.09
0.10
0.13
0.68
0.90
0.85
0.80
0.77
0.70
0.63
Interest Cover
129.84
76.69
4.73
0.40
-0.17
0.23
0.41
1.09
1.06
3.35

News Update:


  • Venus Remedies secures award for antibiotic product Ceftriaxone 1gm from UNICEF
    13th Jun 2024, 09:50 AM

    UNICEF's decision to award the tender to Venus Remedies is a testament to its relentless pursuit of excellence in healthcare

    Read More
  • Venus Remedies gets marketing authorisations from Ukraine for three cancer drugs
    18th Mar 2024, 16:47 PM

    Its total volume of exports to Ukraine stands at $2.20 million

    Read More
  • Venus Remedies obtains Marketing Authorizations for range of essential oncology drugs in Ukraine
    9th Mar 2024, 15:39 PM

    These approvals mark significant progress for Venus Remedies in expanding its market presence and providing access to critical medications for cancer patients in the region

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.